Thrombosis News and Research

Latest Thrombosis News and Research

Researchers examine impact of extreme temperatures on number of deaths

When temperatures are extremely high or low, there is a significant increase in the number of deaths caused by heart failure or stroke.

29 Jul 2014

Cardiovascular Research Foundation to co-sponsor 2014 VEINS conference

VEINS is an established Venous Endovascular Interventional Strategies group comprised of experts in the field whose primary aim is to provide a "How To" meeting for cardiologists and other healthcare providers who are interested in advancing their knowledge and skills in venous interventions and whose ultimate goal is developing their own comprehensive venous interventional program.

25 Jul 2014

Study aims at best way to treat deep vein thrombosis

Patients who have a clot in their legs and are considering whether to be treated with traditional blood-thinning medication or undergo a minimally-invasive catheter-based clot removal procedure should feel comfortable that there is no difference in death rates between the two treatments, although there are more bleeding risks with the catheter procedure, according to a study by Temple University School of Medicine researchers.

22 Jul 2014

Common genetic variation in gene may modify cardiovascular benefit of aspirin

Aspirin is the gold standard for antiplatelet therapy and a daily low-dose aspirin is widely prescribed for the prevention of cardiovascular disease.

21 Jul 2014

Anti-clotting treatment not needed for all kids who undergo spine operations

Blood clots occur so rarely in children undergoing spine operations that most patients require nothing more than vigilant monitoring after surgery and should be spared risky and costly anti-clotting medications, according to a new Johns Hopkins Children's Center study.

16 Jul 2014

Study: History of stroke associated with increased risk of adverse events after elective noncardiac surgery

In an analysis that included more than 480,000 patients who underwent elective noncardiac surgery, a history of stroke was associated with an increased risk of major adverse cardiovascular events and death, particularly if time elapsed between stroke and surgery was less than 9 months, according to a study in the July 16 issue of JAMA.

16 Jul 2014

New technology removes blood clots

When a large blood clot was discovered attached to the end of a catheter inside the right atrial chamber of a patient's heart, doctors faced a daunting challenge.

10 Jul 2014

Complications from partial knee replacement is very small than total knee replacement

Partial knee replacement surgery is safer than total knee replacement, according to a new study published in The Lancet today (July 8).

8 Jul 2014

Members of JUGGLE network collaborate to improve project coordination

The field of life sciences is at the crossroads of biology and medicine and is a key component of the research portfolio of Johannes Gutenberg University Mainz (JGU).

28 Jun 2014

Devon Medical Products gets FDA marketing approval for extriCARE 3600 NPWT pump and foam kit

Global medical device designer and manufacturer Devon Medical Products today announced substantial additions to its Negative Pressure Wound Therapy (NPWT) wound care product line after receiving Food & Drug Administration 510(k) clearance to market its extriCARE 3600 NPWT pump and foam dressing kit.

24 Jun 2014

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

12 Jun 2014

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

Boehringer Ingelheim today announces that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

6 Jun 2014

FCVB 2014 to feature cutting edge research in basic cardiovascular science

Cutting edge research in basic cardiovascular science will be presented at Frontiers in CardioVascular Biology (FCVB) 2014, held 4-6 July at the Palau de Congressos de Catalunya in Barcelona, Spain.

5 Jun 2014

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV).

4 Jun 2014

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to injury is necessary for preserving life, but blood platelets that are over-active, or activated inappropriately because of unstable plaque, can lead to heart attacks and strokes.

3 Jun 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

Pivotal Therapeutics reports reduced revenue in first quarter 2014

Pivotal Therapeutics Inc., ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2014.

31 May 2014

Scientists report that coating stents with vitamin C reduces implants' risks

Every year, more than 1 million people in the U.S. who have suffered heart attacks or chest pain from blocked arteries have little mesh tubes called stents inserted into their blood vessels to prop them open.

29 May 2014

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

29 May 2014

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week.

23 May 2014